NCT03852407View on ClinicalTrials.gov

Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning

PHASE2RecruitingINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

February 4, 2019

Primary Completion Date

November 1, 2033

Study Completion Date

November 1, 2038

Conditions
Acute Myeloid Leukemia in RemissionMyelodysplastic SyndromesChronic Myeloid Leukemia in RemissionMyeloproliferative SyndromeMyeloproliferative DisorderAcute Lymphoid Leukemia in RemissionMultiple MyelomaChronic Lymphoid LeukemiaNon Hodgkin LymphomaHodgkin Lymphoma
Interventions
DRUG

Thymoglobulin

ATG: 2.5 mg /kg/day on day -2 and -1 (day 0 is allogenic transplantation)

DRUG

Melphalan

100mg/m² on day -2

DRUG

Fludarabine

30mg/m² on days -6, -5, -4, -3, and -2

DRUG

Cyclophosphamid

50 mg/kg on days +3 and +4.

Trial Locations (10)

1000

RECRUITING

IJ Bordet, Brussels

1090

RECRUITING

UZ Brussel, Brussels

1200

RECRUITING

UCL St Luc, Brussels

2060

RECRUITING

ZNA Stuivenberg, Antwerp

3000

RECRUITING

UZ Leuven, Leuven

4000

RECRUITING

CHU de Liège, Liège

5530

RECRUITING

CHU UCL Namur Godinne, Yvoir

8000

RECRUITING

AZ Sint Jan Brugge, Bruges

8800

RECRUITING

AZ Delta Roeselare, Roeselare

9000

RECRUITING

UZ Gent, Ghent

All Listed Sponsors
collaborator

Belgian Hematological Society

OTHER

lead

University of Liege

OTHER